277 Towards precision medicine in sepsis 54. Schuts EC, Hulscher M, Mouton JW, Verduin CM, Stuart J, Overdiek H, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and metaanalysis. The Lancet Infectious diseases. 2016;16(7):847-56. 55. Alam N, Oskam E, Stassen PM, Exter PV, van de Ven PM, Haak HR, et al. Prehospital antibiotics in the ambulance for sepsis: a multicentre, open label, randomised trial. The Lancet Respiratory medicine. 2018;6(1):40-50. 56. Hiensch R, Poeran J, Saunders-Hao P, Adams V, Powell CA, Glasser A, et al. Impact of an electronic sepsis initiative on antibiotic use and health care facility-onset Clostridium difficile infection rates. Am J Infect Control. 2017;45(10):1091-100. 57. Sandiumenge A, Diaz E, Rodriguez A, Vidaur L, Canadell L, Olona M, et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother. 2006;57(6):1197-204. 58. Sandiumenge A, Lisboa T, Gomez F, Hernandez P, Canadell L, Rello J. Effect of antibiotic diversity on ventilator-associated pneumonia caused by ESKAPE Organisms. Chest. 2011;140(3):643-51. 59. Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Critical care medicine. 2014;42(7):1714-21. 60. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nature reviews Disease primers. 2016;2:16045. 61. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015;33(32):3817-25. 62. Von Hoff DD, Stephenson JJ, Jr., Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877-83. 63. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18(22):6373-83. 64. Kim ES, Herbst RS, Wistuba, II, Lee JJ, Blumenschein GR, Jr., Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44-53. 65. Do K, O’Sullivan Coyne G, Chen AP. An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin Clin Oncol. 2015;4(3):31. 66. Dzau VJ, Ginsburg GS. Realizing the Full Potential of Precision Medicine in Health and Health Care. Jama. 2016;316(16):1659-60. 67. Vincent JL. The coming era of precision medicine for intensive care. Critical care (London, England). 2017;21(Suppl 3):314. 68. Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive care medicine. 2015;41(5):776-95. 69. Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive care medicine. 2017. 70. Watkins RR, Smith TC, Bonomo RA. On the path to untreatable infections: colistin use in agriculture and the end of ‘last resort’ antibiotics. Expert Rev Anti Infect Ther. 2016;14(9):7858. 71. Yin W, Li H, Shen Y, Liu Z, Wang S, Shen Z, et al. Novel Plasmid-Mediated Colistin Resistance Gene mcr-3 in Escherichia coli. MBio. 2017;8(3). 72. Sharrer GT. Personalized medicine: ethics for clinical trials. Methods Mol Biol. 2012;823:3548. 11
RkJQdWJsaXNoZXIy MTk4NDMw